La cadena de opciones muestra datos clave de las opciones de acciones de Vir Biotechnology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Vir Biotechnology..

Vir Biotechnology (NASDAQ:VIR) Bolsa, Cadena de Opciones

VIR BIOTECHNOLOGY INC

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Virtu Financial, Inc. Class A Common Stock

Virtu Financial Inc

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Viratech Corp

Neuralbase AI Ltd

VIRIDIAN METALS INC by VIRIDIAN METALS INC

Pacer Funds Trust BioThreat Strategy ETF

Viracta Therapeutics Inc

Press Releases

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

Astria Therapeutics

ArriVent BioPharma

Bicara Therapeutics

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Geron

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kura Oncology

MeiraGTx Hldgs

MapLight Therapeutics, Inc. - Common Stock

MapLight Therapeutics

Myriad Genetics

Nanobiotix

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

RAPT Therapeutics

Replimune Group

Rezolute

ARS Pharmaceuticals

Savara

Tyra Biosciences

Valneva

HC Wainwright & Co.

Evercore ISI Group

B of A Securities

Raymond James

Needham

Comments

Vir Biotechnology

Vir Biotechnology (VIR) Opciones

Vir Biotechnology (NASDAQ:VIR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL